Clinical Trials Browser

Approved for marketing × Neuroendocrine Tumors × lutetium Lu 177 dotatate × Clear all

NCT02705313 2018-04-09

EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx

Approved for marketing

Neuroendocrine Tumors